-
公开(公告)号：US10899802B2
公开(公告)日：2021-01-26
申请号：US15728610
申请日：2017-10-10
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC分类号： C07K14/22 , A61K39/00 , C12N7/00 , A61K39/13 , A61K39/295 , A61K39/095 , A61K39/12 , A61K39/39
摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20200368340A1
公开(公告)日：2020-11-26
申请号：US16984499
申请日：2020-08-04
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Leena Shriram Bagle , Amardeep Singh Bhupender Bhalla , Miguel Angel Garcia , Lei Hu , Lakshmi Khandke , Avvari Krishna Prasad , Cindy Xudong Yang
摘要： The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US10751402B2
公开(公告)日：2020-08-25
申请号：US15800373
申请日：2017-11-01
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Leena Shriram Bagle , Amardeep Singh Bhupender Bhalla , Miguel Angel Garcia , Lei Hu , Lakshmi Khandke , Avvari Krishna Prasad , Cindy Xudong Yang
摘要： The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US10226525B2
公开(公告)日：2019-03-12
申请号：US15144884
申请日：2016-05-03
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G. K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
IPC分类号： A61K39/00 , C07K16/12 , C07K16/44 , A61K39/40 , A61K39/09 , A61K39/39 , A61K47/10 , A61K47/26
摘要： The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20180125958A1
公开(公告)日：2018-05-10
申请号：US15800373
申请日：2017-11-01
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Leena Shriram Bagle , Amardeep Singh Bhupender Bhalla , Miguel Angel Garcia , Lei Hu , Lakshmi Khandke , Avvari Krishna Prasad , Cindy Xudong Yang
摘要： The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号：US20180022783A1
公开(公告)日：2018-01-25
申请号：US15728610
申请日：2017-10-10
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC分类号： C07K14/22 , A61K39/39 , A61K39/295 , A61K39/00 , A61K39/12 , A61K39/095 , C12N7/00 , A61K39/13
摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US11730800B2
公开(公告)日：2023-08-22
申请号：US17024618
申请日：2020-09-17
申请人： PFIZER INC.
发明人： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC分类号： A61K39/095 , A61K47/64 , C07K14/22 , C07K16/12 , A61K39/00 , A61K47/18 , A61K47/10 , A61K47/26 , A61K31/7028 , A61P31/00 , A61K39/12
CPC分类号： A61K39/095 , A61K31/7028 , A61K39/12 , A61K47/10 , A61K47/183 , A61K47/26 , A61K47/646 , A61K47/6415 , A61P31/00 , C07K14/22 , C07K16/1217 , A61K2039/545 , A61K2039/55 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , C12N2770/32434
摘要： In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
8.发明公开公开(公告)号：US20230218735A1
公开(公告)日：2023-07-13
申请号：US18001953
申请日：2021-06-17
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Alexey Vyacheslavovitch Gribenko , William Carl Gruber , Kathrin Ute Jansen , Lakshmi Khandke , Nicholas Randolph Everard Kitchin , Jody Lawrence , Yahong Peng , Michael William Pride , Christopher Frederick Webber , Sabine Susanne Wellnitz , Zhuobiao Yi
CPC分类号： A61K39/08 , A61K47/26 , A61K9/19 , C07K16/1282 , A61P31/04 , A61K2039/55577
摘要： In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
公开(公告)号：US11680087B2
公开(公告)日：2023-06-20
申请号：US17126712
申请日：2020-12-18
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Rasappa Gounder Arumugham , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Kathrin Ute Jansen , Thomas Richard Jones , Lakshmi Khandke , Bounthon Loun , John Lance Perez , Gary Warren Zlotnick
IPC分类号： A61K39/05 , C07K14/22 , A61K39/00 , A61K39/13 , A61K39/295 , A61K39/095 , A61K39/12 , A61K39/39 , C12N7/00
CPC分类号： C07K14/22 , A61K39/0016 , A61K39/095 , A61K39/12 , A61K39/13 , A61K39/295 , A61K39/39 , C12N7/00 , A61K2039/5252 , A61K2039/545 , A61K2039/55505 , A61K2039/55511 , A61K2039/70 , C12N2710/20034 , C12N2770/32634 , Y02A50/30
摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.
-
公开(公告)号：US20220000999A1
公开(公告)日：2022-01-06
申请号：US17474561
申请日：2021-09-14
申请人： Pfizer Inc.
发明人： Annaliesa Sybil Anderson , Leena Shriram Bagle , Amardeep Singh Bhupender Bhalla , Miguel Angel Garcia , Lei Hu , Lakshmi Khandke , Avvari Krishna Prasad , Cindy Xudong Yang
摘要： The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
-
-
-
-
-
-
-
-
搜索结果
31 条记录 (耗时 0.034 秒)
